SEC Form 4
AIM ImmunoTech Inc. (AIM) insider trading
In the 12 months to Nov 7, 2026, one AIM insider reported open-market purchases of $26.8K across 7 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $26.8K
- 7 filings · Thomas K. Equels, CEO & President
Who traded AIM, and when
- Purchase
AIM daily close from Nov 7, 2025 to Nov 6, 2026, between $0.15 and $1.68, last $0.16. 0 sale and 7 purchase filings by 1 insider, marked at their filing dates. Thomas K. Equels, CEO & President: bought $26.8K across 7 filings, first filed Sep 15, 2026, last Nov 6, 2026.
Largest mark · tap a row for others
Thomas K. Equels · CEO & President
Filing 1 of 4 within a week · $13,456 total
Purchase $1,292
5,900 shares at $0.22 avg
Filed Sep 15, 2026 · traded Sep 14
Close on filing date $0.21
Thomas K. Equels · CEO & President
CEO & President
$26.8K boughtOpen-market trades
7 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Thomas K. Equels | CEO & President | — | $26.8K | 7 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Thomas K. Equels CEO & President | Purchase | 20,299 | $0.16 | $3.2K | 210,046 | |
traded | Thomas K. Equels CEO & President | Purchase | 31,675 | $0.16 | $5.1K | 189,747 | |
traded | Thomas K. Equels CEO & President | Purchase | 31,250 | $0.16 | $5.1K | 158,072 | |
traded | Thomas K. Equels CEO & President | Purchase | 24,000 | $0.21 | $5.0K | 126,822 | |
traded | Thomas K. Equels CEO & President | Purchase | 11,000 | $0.21 | $2.3K | 102,822 | |
traded | Thomas K. Equels CEO & President | Purchase | 22,000 | $0.22 | $4.9K | 91,822 | |
traded | Thomas K. Equels CEO & President | Purchase | 5,900 | $0.22 | $1.3K | 69,822 |
GET /stocks/filings/vX/form-4?tickers=AIM&filing_date.gte=2025-11-07&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"AIM"
],
"issuer_cik": "0000946644",
"owner_cik": "0001450324",
"accession_number": "0001493152-26-050412",
"form_type": "4",
"filing_date": "2026-11-06",
"period_of_report": "2026-11-06",
"issuer_name": "AIM ImmunoTech Inc.",
"issuer_trading_symbol": "AIM",
"owner_name": "Equels Thomas K",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CEO & President",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-06",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 20299,
"transaction_price_per_share": 0.156,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 210046,
"transaction_value": 3166.644,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
},
{
"tickers": [
"AIM"
],
"issuer_cik": "0000946644",
"owner_cik": "0001450324",
"accession_number": "0001493152-26-048460",
"form_type": "4",
"filing_date": "2026-10-26",
"period_of_report": "2026-10-23",
"issuer_name": "AIM ImmunoTech Inc.",
"issuer_trading_symbol": "AIM",
"owner_name": "Equels Thomas K",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CEO & President",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-23",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 31675,
"transaction_price_per_share": 0.16,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 189747,
"transaction_value": 5068,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 3 records
- Grants and awards1 record
- Other2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has AIM ImmunoTech Inc.'s CEO sold stock?
No. Thomas K. Equels (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is AIM’s insider data?
These are AIM Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track AIM insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for AIM every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.